80例慢性HBV感染者临床与肝组织病理学分析*

doi:10.3969/j.issn.1672-5069.2014.05.011

摘要/Abstract

摘要： 目的探讨血清丙氨酸氨基转移酶(ALT)低于2倍正常值上限(ULN)的慢性乙型肝炎病毒(HBV)感染者临床特征和肝组织病理学的变化。方法在2010年7月至2013年11月住院行肝活检的80例慢性HBV感染者,常规检测血清HBeAg和HBV DNA水平,回顾性分析其临床资料和肝组织学改变。结果50例HBeAg阳性和30例HBeAg阴性患者年龄分别为（28.52±9.10）岁和（39.37±10.14）岁,HBV DNA载量分别为（7.79±0.73） lg拷贝/毫升和（4.52±1.67） lg拷贝/毫升,差异均有统计学意义（P<0.01）;两组肝组织炎症活动度分别为（1.00±0.57）和（1.27±0.45）,纤维化程度分别为（0.38±0.57）和（1.07±1.11）,差异均有统计学意义（P<0.05）;两组肝组织HBsAg表达强度免疫染色评分（ISS）分别为（0.93±0.92）和（0.77±0.93）,HBcAg分别为（1.58±0.88）和（1.63±0.92）,差异均无统计学意义（P>0.05）;22例患者年龄≥40岁和35例年龄<30岁患者肝组织炎症活动度分别为（1.32±0.48）和（0.69±0.58）,纤维化程度分别为（1.00±1.27）和（0.40±0.50）,差异均有统计学意义（P<0.05）;52例男性和28例女性患者肝组织炎症活动度分别为（1.12±0.55）和（1.07±0.54）,纤维化程度分别为（0.71±0.82）和（0.50±0.96）,肝组织HBsAg表达强度（ISS）分别为（0.89±0.89）和（0.82±1.00）,HBcAg分别为（1.44±0.94）和（1.24±1.09）,差异均无统计学意义。结论对年龄≥40岁且HBeAg阴性的血清ALT低于2×ULN的慢性HBV感染者,应及早行肝组织病理学检查,以进行正确的病情评估。

关键词: 慢性乙型肝炎, 丙氨酸氨基转移酶, 临床特征, 肝组织, 病理学

Abstract: Objective To explore the liver histological changes and HBsAg and HBcAg expression in patients with chronic hepatitis B and low serum alanine aminotransferase（ALT） levels （<2×upper limit of normal,ULN）. Methods Eighty patients with chronic hepatitis B virus infection received liver biopsies from July 2010 to November 2013 in this study. The liver histopathologic changes were analyzed and HBsAg and HBcAg expression in liver tissues were detected by immunostaining. Results The average age in 50 HBeAg-positive patients was （28.52±9.10） years,significantly younger than 30 HBeAg-negative patients [（39.37±10.14）years,P<0.01];The serum HBV DNA load in HBeAg-positive patients was （7.79±0.73） lg copies/ml,significantly higher than that in HBeAg-negative patients[（4.52±1.67） lg copies/ml,P<0.01];The liver inflammation grades and fibrosis staging in HBeAg-positive patients were（1.00±0.57） and （0.38±0.57）,significantly lower than those in HBeAg-negative patients [（1.27±0.45） and （1.07±1.11）,repectively,P<0.01];There were no significant differences in immunostaining scores （ISS） of HBsAg [（0.93±0.92）and （0.77±0.93）,P>0.05] or HBcAg [（1.58±0.88） and （1.63±0.92）,P>0.05] between the two groups;The liver histological inflammation grades and fibrosis staging in 22 patients over 40 years of age were （1.32±0.48） and （1.00±1.27）,respectively,significantly higher than those in 35 patients younger than 30 years of age [（0.69±0.58） and （0.40±0.50）,respectively,P<0.01];No significant differences were observed between both genders in either liver inflammation grades [（1.12±0.55） and（1.07±0.54）] or fibrosis staging [（0.71±0.82） and （0.50±0.96）];There were no significant differences in ISS of HBsAg [（0.89±0.89） and （0.82±1.00）] or HBcAg [（1.44±0.94） and （1.24±1.09）] between males and females. Conclusions Patients over 40 years of age with hepatitis B virus infection are recommended for liver biopsies in time in order to elucidate the histopathological changes.

Key words: Hepatitis B, Alanine aminotransferase, Clinical features, Liver, Pathology

徐葵花, 常海宁, 承泽农, 赵守松. 80例慢性HBV感染者临床与肝组织病理学分析^*[J]. 实用肝脏病杂志, 2014, 17(5): 489-493.

Xu Kuihua, Chang Haining, Cheng Zenong. Liver histological changes and HBsAg and HBcAg expression in patients with chronic hepatitis B and low serum ALT levels[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(5): 489-493.

参考文献

[1] Liang X,Bi S,Yang W,et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine,2009,27（47）:6550-6557.
[2] Liang X,Bi S,Yang W,et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis,2009,200（1）:39-47.
[3] Alam S,Ahmad N,Mustafa G,et al. Evaluation of normal or minimally elevated alanine transaminase,age and DNA level in predicting liver histological changes in chronic hepatitis B. Liver Int,2011,31（6）:824-830.
[4] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）:81-89.
[5] 中华医学会传染病与寄生虫病学分会,中华医学会肝病学分会.病毒性肝炎防治方案.中华肝脏病杂志,2000,8（6）:324-329.
[6] Macpherson AM,Archer DF,Leslie S,et al. The effect of etonogestrel on VEGF,oestrogen and progesterone receptor immunoreactivity and endothelial cell number in human endometrium. Hum Reprod,1999,14 （12）:3080-3087.
[7] Kim CW,Yoon SK,Jung ES,et al. Correlation of hepatitis B core antigen and beta-catenin expression on hepatocytes in chronic hepatitis B virus infection:relevance to the severity of liver damage and viral replication. J Gastroenterol Hepatol,2007,22（9）:1534-1542.
[8] Andreani T,Serfaty L,Mohand D,et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection:histologic findings and outcome. Clin Gastroenterol Hepatol,2007,5（5）: 636-641.
[9] McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology,2009,49（Suppl 5）:S45-S55.
[10] 陆传统,周文红,胡爱荣.HBeAg阴性慢性乙型肝炎患者血清病毒载量与肝组织学改变的关系.中华实验和临床病毒学杂志,2010,24（3）:184-186.
[11] Liaw YF,Leung N,Kao JH,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int,2008,2（3）:263-283.
[12] Lai CL,Ratziu V,Yuen MF,et al. Viral hepatitis B. Lancet, 2003,362（9401）:2089-2094.
[13] 秦恩强,赵鹏,张新伟,等.血清ALT持续正常及HBeAg阴性慢性HBV感染者86例肝脏病理特征分析.临床内科杂志,2009,26（4）:251-253.
[14] Tsang PS,Trinh H,Garcia RT,et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol,2008,6（5）:569-574.

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	汪道伟, 方坚, 范凌. 自身免疫性肝炎患者血清IL-21和趋化因子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 844-847.
[6]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[7]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[8]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	吴欣, 郭杨志, 杜霄壤, 吴孟晋, 朱云, 冯兴中. 75例中药诱导的肝损伤患者临床特征分析*[J]. 实用肝脏病杂志, 2019, 22(5): 668-671.
[11]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[12]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[13]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[14]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[15]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.

80例慢性HBV感染者临床与肝组织病理学分析^*

Liver histological changes and HBsAg and HBcAg expression in patients with chronic hepatitis B and low serum ALT levels

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价